HRP20170702T1 - Inhibitori proteazoma za liječenje karcinoma - Google Patents

Inhibitori proteazoma za liječenje karcinoma Download PDF

Info

Publication number
HRP20170702T1
HRP20170702T1 HRP20170702TT HRP20170702T HRP20170702T1 HR P20170702 T1 HRP20170702 T1 HR P20170702T1 HR P20170702T T HRP20170702T T HR P20170702TT HR P20170702 T HRP20170702 T HR P20170702T HR P20170702 T1 HRP20170702 T1 HR P20170702T1
Authority
HR
Croatia
Prior art keywords
bortezomib
administered
cancer
multiple doses
patient
Prior art date
Application number
HRP20170702TT
Other languages
English (en)
Croatian (hr)
Inventor
Roland De Coster
Helgi Van De Velde
Martine Bayssas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43629456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170702(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20170702T1 publication Critical patent/HRP20170702T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20170702TT 2009-10-01 2010-10-01 Inhibitori proteazoma za liječenje karcinoma HRP20170702T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24771409P 2009-10-01 2009-10-01
PCT/EP2010/005994 WO2011038924A2 (en) 2009-10-01 2010-10-01 Treatment of disease with proteasome inhibitors
EP10807320.6A EP2519231B1 (en) 2009-10-01 2010-10-01 Proteasome inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
HRP20170702T1 true HRP20170702T1 (hr) 2017-07-14

Family

ID=43629456

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170702TT HRP20170702T1 (hr) 2009-10-01 2010-10-01 Inhibitori proteazoma za liječenje karcinoma

Country Status (18)

Country Link
US (1) US20110189204A1 (https=)
EP (1) EP2519231B1 (https=)
JP (1) JP2013506626A (https=)
AU (2) AU2010300259A1 (https=)
CA (1) CA2776327A1 (https=)
CY (1) CY1118925T1 (https=)
DK (1) DK2519231T3 (https=)
ES (1) ES2624644T3 (https=)
HR (1) HRP20170702T1 (https=)
HU (1) HUE032571T2 (https=)
LT (1) LT2519231T (https=)
ME (1) ME02725B (https=)
PL (1) PL2519231T3 (https=)
PT (1) PT2519231T (https=)
RS (1) RS55931B1 (https=)
SI (1) SI2519231T1 (https=)
SM (1) SMT201700231T1 (https=)
WO (1) WO2011038924A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039328B (zh) * 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
CA2966288A1 (en) * 2014-10-30 2016-05-06 Big Dna Ltd Combination therapy
WO2017070328A1 (en) * 2015-10-20 2017-04-27 The Cleveland Clinic Foundation STIMULATION OF 11β-HSD2 EXPRESSION TO IMPROVE HORMONAL THERAPY OF STEROID-DEPENDENT DISEASE
US11947330B2 (en) * 2019-03-06 2024-04-02 The Boeing Company Tool orientation systems and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499802A (en) * 1982-09-29 1985-02-19 Container Graphics Corporation Rotary cutting die with scrap ejection
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5081110A (en) * 1986-03-27 1992-01-14 Sloan-Kettering Institute For Cancer Research Method of killing sarcoma cells using fludarabine phosphate and ionizing radiation
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CN1339970A (zh) * 1999-02-10 2002-03-13 鹤尾隆 抗癌药物增强剂
JP4162491B2 (ja) * 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
KR20070107707A (ko) 2005-01-21 2007-11-07 아스텍스 테라퓨틱스 리미티드 피라졸 키나제 억제제와 추가 항종양제의 조합물
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
US20060193844A1 (en) * 2005-02-28 2006-08-31 Proteolix, Inc. Methods for enzyme inhibition
EP1876893B1 (en) * 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2008086005A1 (en) * 2007-01-09 2008-07-17 University Of South Florida Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
MX2010002179A (es) * 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.

Also Published As

Publication number Publication date
AU2010300259A1 (en) 2012-04-26
ES2624644T3 (es) 2017-07-17
PT2519231T (pt) 2017-05-25
JP2013506626A (ja) 2013-02-28
SMT201700231T1 (it) 2017-07-18
WO2011038924A9 (en) 2011-07-14
US20110189204A1 (en) 2011-08-04
SI2519231T1 (sl) 2017-07-31
EP2519231B1 (en) 2017-03-15
WO2011038924A3 (en) 2011-05-26
PL2519231T3 (pl) 2017-09-29
LT2519231T (lt) 2017-05-10
EP2519231A2 (en) 2012-11-07
DK2519231T3 (en) 2017-06-26
AU2016277700A1 (en) 2017-02-02
CY1118925T1 (el) 2018-01-10
ME02725B (me) 2017-10-20
HUE032571T2 (en) 2017-09-28
WO2011038924A2 (en) 2011-04-07
RS55931B1 (sr) 2017-09-29
CA2776327A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
JP2015520753A5 (https=)
RU2014147105A (ru) 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
RU2010142390A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
WO2016133903A3 (en) Combination therapy for cancer treatment
JP2011103891A5 (https=)
RU2019142694A (ru) Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний
MX2009007597A (es) Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
NZ596739A (en) Methods of treating proliferative diseases
HRP20170702T1 (hr) Inhibitori proteazoma za liječenje karcinoma
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
JP2017214420A (ja) 樹状細胞癌ワクチンのための小分子エンハンサー
RU2015152785A (ru) Лечение злокачественной опухоли налтрексоном
WO2020132560A3 (en) Compositions and methods for cancer therapy
IL259512B1 (en) Combination for effective treatment of metastatic cancer in patients
IL164564A0 (en) Combination therapy for the treatment of cancer
JP2013506626A5 (https=)
PH12021552977A1 (en) Methods of treating urinary system cancers
JP2018511642A5 (https=)
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
RU2013149175A (ru) Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы
WO2020053664A8 (en) Combination therapy for the treatment of estrogen-receptor positive breast cancer
EA200601471A1 (ru) Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты)
BR112021023372A2 (pt) Método para o tratamento do câncer com uma forma de dosagem oral de um receptor de inibidor-alfa de estrogênio